Members of the epidermal growth factor receptor (EGFR) or ErbB/ HER family and their activating ligands are essential regulators of diverse developmental processes 1, 2 . Inappropriate activation of these receptors is a key feature of many human cancers 3 , and its reversal is an important clinical goal. A natural secreted antagonist of EGFR signalling, called Argos, was identified in Drosophila 4 . We showed previously that Argos functions by directly binding (and sequestering) growth factor ligands that activate EGFR 5 . Here we describe the 1.6-Å resolution crystal structure of Argos bound to an EGFR ligand. Contrary to expectations 4, 6 , Argos contains no EGF-like domain. Instead, a trio of closely related domains (resembling a three-finger toxin fold 7 ) form a clamp-like structure around the bound EGF ligand. Although structurally unrelated to the receptor, Argos mimics EGFR by using a bipartite binding surface to entrap EGF. The individual Argos domains share unexpected structural similarities with the extracellular ligand-binding regions of transforming growth factor-b family receptors 8 . The three-domain clamp of Argos also resembles the urokinase-type plasminogen activator (uPA) receptor, which uses a similar mechanism to engulf the EGF-like module of uPA 9 . Our results indicate that undiscovered mammalian counterparts of Argos may exist among other poorly characterized structural homologues. In addition, the structures presented here define requirements for the design of artificial EGF-sequestering proteins that would be valuable anti-cancer therapeutics.
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The 419-residue mature Drosophila melanogaster Argos was modified to improve crystallization by removing a poorly conserved region with multiple O-linked glycosylation sites (residues 1-87). In addition, a non-conserved 120-residue insert (residues 140-259) exclusive to drosophilid Argos molecules was replaced with the corresponding five amino acids (PDGRT) from Apis mellifera Argos ( Supplementary Fig. 1 ). The resulting 217-residue protein (Argos 217 ) has greatly improved stability and purification properties, and binds Spitz with an affinity (K d 5 7.7 nM; Supplementary Fig. 2 ) similar to that previously measured 5 for full-length Argos 419 (K d 5 20 nM). Triclinic crystals of Argos 217 bound to the Spitz EGF-domain (Spitz EGF , residues 48-99) grew at neutral pH with two complexes per asymmetric unit, and diffracted to 1.6 Å resolution. The structure was solved by multiwavelength anomalous dispersion (MAD), using the halide soak method 10 (Supplementary Table 1 ). Representative regions of electron density are shown in Fig. 1a , b. Structures of uncomplexed Argos 217 and Spitz EGF were also determined (to 2.5 and 1.5 Å , respectively) by molecular replacement.
Argos consists of three separate disulphide-bonded b-sheet domains (domains 1-3) that bear no resemblance to EGF domains. This three-domain composition was not discerned in sequence analyses. The three domains of Argos engulf the bound Spitz EGF molecule with a structure that is reminiscent of a C-clamp (Fig. 1c, d ). Domains 2 and 3 constitute the 'jaws' of this clamp and make an intimate set of direct contacts with bound Spitz EGF . Domain 1 forms the backbone of the C-clamp and does not contribute directly to ligand binding. Spitz EGF itself is very similar in structure to other known EGFR family ligands ( Supplementary Fig. 3 ). Its three disulphide bonds generate three loops in the typical EGF domain structure, which are termed the A-loop, the B-loop and the C-loop (Fig. 1e) . The Spitz B-loop protrudes into the crevice between domains 2 and 3 of Argos (Fig. 1c, d ). The conformation of Spitz EGF is largely unaltered on binding to Argos, apart from small changes in the backbone at the B-loop tip ( Supplementary Fig. 3 ) and the reorientation of certain interfacial side chains. Domains 1, 2 and 3 of Argos superimpose remarkably well (with C a root mean squared deviations of 1.3-1.9 Å ) despite sharing little sequence identity (less than 30%). The overall architecture found in all three domains is shown in Fig. 2a . The cysteine residues form a disulphide-bonded core, from which two b-hairpins project to form a four-stranded b-sheet with a relatively unusual antiparallel 2143 topology 11 . The result is a flat domain that resembles part of a left hand, with the b-hairpins as two fingers plus a thumb-like projection emerging from the disulphide-bonded core. In domains 1 and 3 (but not domain 2), a knuckle-like protrusion also projects below the plane of the page in Fig. 2a . The positions of the C1-C3 and C4-C6 disulphides are almost identical in all three Argos domains (Fig. 2b) , but the third (C2-C5) disulphide is missing from domain 2. The absence of this disulphide correlates with the lack of a knuckle in domain 2. Domain 1 is distinguished by the presence of a unique additional N-terminal b-strand (b19) that is parallel to strand b2. The drosophilid-specific insertion in Argos occurs at the top of domain 1 in the orientation shown in Fig. 2 , immediately before the knuckle (between C4 and C5). This insertion would probably project out and away from domain 1, with its ends constrained by the C2-C5 and C4-C6 disulphides.
Protein Data Bank searches with the DALI server 12 and a secondarystructure-matching algorithm 13 revealed that the three domains of Argos are significantly related to the three-finger toxin fold found in snake neurotoxins and cardiotoxins 7 -although the disulphidebonding pattern is altered, and Argos has just two (rather than three) fingers per domain. Interestingly, the three-finger toxin fold is also found in the extracellular ligand-binding domains of receptors for transforming growth factor-b (TGF-b) family ligands 8 . As shown in Fig. 2c , two fingers of the extracellular ligand-binding domain of the type II activin receptor (ActRII) 14 overlay very well with domain 3 of Argos. Members of the Ly-6 superfamily also share this fold 7 , including the receptor for uPA (ref. 9) .
Argos 'clamps' Spitz EGF between domains 2 and 3 ( Fig. 1c, d ) and buries 35% of the ligand's surface. Domains 2 and 3 are roughly parallel to one another ( Fig. 1c) and are stacked so that they present opposite surfaces to the Spitz EGF molecule sandwiched between them. With the hand analogy introduced above, domain 3 presents its palm to the bound ligand, whereas domain 2 contacts Spitz EGF using the back of the hand. The Spitz-binding regions on domains 2 and 3 can each be divided into two sites ( Fig. 3) : an A site and a B site.
The A sites (d2A, d3A) lie on the b-sheet surfaces, and the B sites (d2B, d3B) involve the thumb and disulphide-bonded core. Site A on domain 2 (d2A) consists of a patch of hydrophobic side chains on the back-of-hand surface of fingers 1 and 2 (L301, L326, Y341 and F343), which makes van der Waals contacts with three aliphatic side chains from the Spitz B-loop (V72, I74 and V79). Site B on domain 2 (d2B) comprises a flat surface (cyan in Fig. 3 ) formed by side chains from the base of finger 2 (V323, Y325, S346 and P347) and the domain 2 thumb (F294). This flat surface packs against the carboxy-terminal part of Spitz EGF , contacting M89, Q91 and Y95 in the C-loop. We previously identified S346 and P347 from site d2B as significant residues in a genetic screen for modifiers of an Argos misexpression phenotype in Drosophila eye development 15 . S346 and P347 are both conserved in all known Argos orthologues (Supplementary Fig. 1 ) and make direct hydrogen bonds with Spitz (Fig. 3) . In domain 3, part of site A (d3A) involves polar side chains on the palm side of finger 1 (T363, R365, E373 and N375) that interact with the Spitz EGF B-loop. In addition, a cluster of hydrophobic side chains around the tip of finger 2 (F403, L404 and I408) contact residues from the Spitz EGF N terminus, A-loop and B-loop. A key feature of this interaction is the projection of the F403 and L404 side chains into a hydrophobic pocket on the Spitz surface formed by Y52, P55, P78 and Y80 (Fig. 3) . In the B-site on domain 3 (d3B), side chains close to the base of the two fingers (Q357, P358, L361, N377 and S412) form a binding site for the Spitz A-loop helix (contacting Spitz T57, F58, W61 and Y62). Site d3B also accommodates the side chains of Spitz R92 and L64 (Fig. 3 ).
Despite having a completely different structural scaffold from EGFR, Argos mimics the characteristic bipartite capture of growth factor seen in ligand-bound structures of the EGFR extracellular region (sEGFR) 16, 17 . Argos presents two ligand-binding surfaces that closely resemble those in EGFR. Specifically, domain 2 of Argos mimics domain I of sEGFR in its ligand contacts, whereas domain 3 of Argos emulates sEGFR domain III (Fig. 4a) . The primary ligand contacts made by domain 2 of Argos and domain I of EGFR are remarkably similar. Both use a central hydrophobic patch that interacts with a similar region of the B-loop of the bound EGF domain. As shown in Fig. 4a (upper panels), Argos site d2A and EGFR site 1 (from ref. 17 ) are very similar, with a comparable arrangement of hydrophobic side chains making ligand contacts in each case. The second binding site on Argos domain 2 (d2B) also recapitulates many other contacts between sEGFR domain I and human EGF (hEGF), but it is different in detail. Along the same lines, site B on Argos domain 3 (d3B) recapitulates site 2 in the sEGFR/hEGF interface 17 ( Fig. 4a , lower panels), including interactions with an arginine residue that is critical for hEGF binding to its receptor (R41 in hEGF, R92 in Spitz). Both sites accommodate three key ligand side chains (Y13, L15 and R41 in hEGFR; Y62, L64 and R92 in Spitz) in analogous binding sites. Site 3 on domain III of EGFR is not mimicked by Argos; the C terminus of the bound EGF domain is much more exposed in the Spitz EGF -Argos complex than in the hEGF-sEGFR complex (Fig. 4a) . Argos compensates for the absence of these site 3 interactions with an extensive set of unique contacts mediated by site d3A (Fig. 4a) .
Overall, Argos domain 2 buries slightly less surface on Spitz EGF (560 Å 2 ) than EGFR domain I buries on hEGF (745 Å 2 ) 17 , but it includes more apolar surface (68%) than in the EGFR domain I/hEGF interface (56%). Argos domain 3 buries slightly more of its bound EGF domain (843 Å 2 ; 65% apolar) than does sEGFR domain III (819 Å 2 ; 62% apolar). Each interface has a shape complementarity parameter, S c (ref. 18 ), of 0.70, which is typical for strong protein/ protein interfaces and reflects a significantly greater shape complementarity than is seen in antibody/antigen interfaces. The fact that Spitz EGF binds about tenfold more strongly to Argos than to the Drosophila EGFR extracellular region may reflect different requirements for domain rearrangements in the two binding proteins. Clearly defined sets of (intramolecular) contacts between domains 1 and 2 and between domains 1 and 3 ( Supplementary Fig. 4 bound, interactions between domains 1 and 3 in the complex may slow the dissociation of Spitz EGF . About half of the residues involved in the binding of Spitz EGF to Argos are conserved in hEGF and/or human TGF-a, which may explain the ability of Argos to bind detectably (although weakly, with a K d of about 5 mM) to hEGF (not shown). Sequence analyses have failed to identify clear homologues of Argos in vertebrates, but this does not necessarily mean that functional mammalian analogues do not exist. The amino-acid sequence of Argos has been unusually cryptic, providing few (or misleading) clues about the structure of the protein. It only became apparent that Argos has three distinct domains (and no EGF-like domain) once the structure described here was determined. Moreover, the relationship of the constituent domains in Argos to the three-finger toxin fold can be seen only in structural (and not sequence) comparisons. As shown in Fig. 2c , the individual domains of Argos share unexpected and striking structural similarity with the extracellular ligand-binding regions of receptors for TGF-b/bone morphogenetic protein (BMP) family ligands, which consist of little more than a single three-finger toxin fold 8, 14 . As shown in Supplementary Fig. 7 , the positions of the ligand-binding sites in Argos domain 3 and the extracellular regions of TGF-b/BMP family receptors also correspond strikingly well. Both use the palm side of the domain as defined in the analogy drawn in Fig. 2a .
Among human proteins that contain three-finger toxin fold domains, one intriguing example uses three such modules to engulf an EGF-like domain. This is the cell-surface receptor for uPA 9, 19 , which is an unexpected structural homologue of Argos. As shown in Fig. 4b , the three domains from the uPA receptor (uPAR) form a clamp-like structure around the EGF domain found at the N terminus of uPA. Each domain presents its palm side to the bound ligand (like Argos domain 3). The uPAR structure resembles the clamp formed around the Spitz EGF domain by Argos (Fig. 1c, d ). There are differences in the orientation of the bound EGF domain in the Argos-Spitz and uPAR-uPA complexes. Moreover, Argos has one of its three constituent domains (domain 2) 'inverted' so that it presents the back (rather than the palm) of the hand to the ligand. However, the correspondence in overall architecture and function (as proteins that entrap EGF domains) between uPAR and Argos suggests that other structural homologues of Argos should be sought in mammals. There are many human uPAR/Ly6 domain-containing proteins for which the function remains unclear. Several, such as CD177/PRV-1 and C4.4A, contain multiple three-finger domains 20, 21 like uPAR. Moreover, C4.4A expression is known to be altered in several metastatic human cancers 22 . We suggest that one of these numerous structural homologues might represent a functional analogue of Argos. Even if such an analogue does not exist, the known human proteins from this class could clearly be used as structural scaffolds in the design of protein therapeutics that will sequester ErbB receptor-activating EGF domains.
It is increasingly clear that excessive or unregulated expression (or shedding) of ErbB-family ligands is important in numerous cancers, through autocrine and/or paracrine activation of cell growth [23] [24] [25] [26] [27] . The role of ErbB ligands may be particularly important in cancers for which available receptor-targeted approaches have failed or have met resistance 26 . In these (and other) cases, therapeutic agents that neutralize ErbB receptor ligands are likely to have great value. The understanding of Spitz neutralization by Argos that we present here provides avenues to explore in efforts to identify a human homologue of Argos. The structural lessons also provide clear suggestions for which human proteins might be used as scaffolds for generating protein therapeutics that sequester aberrantly produced EGF-like growth factors-exploiting a mechanism for inhibiting EGFR signalling that has evolved naturally.
METHODS SUMMARY
Protein purification and crystallization. Argos 217 was produced in baculovirus-infected Spodoptera frugiperda Sf9 cells, using the N-terminal BiP signal sequence to direct the secretion of the protein into the medium. The protein has a hexahistidine tag at its C terminus, which was used for purification and sEGFR domain III. Sites 2 and 3 in the sEGFR/hEGF interface are marked with blue ovals. Argos site d3B mimics sEGFR site 2, but Argos does not mimic sEGFR site 3. Instead, Argos makes a unique set of interactions with Spitz EGF (site d3A). A key aliphatic side chain critical for the binding of hEGF to site 3 of EGFR (L47 in hEGF, I98 in Spitz) is disordered and exposed in the Spitz EGF -Argos complex. b, Domain organization of uPAR 9, 19 . The three domains in uPAR are coloured with the order used for Argos in Fig. 1 . Like Argos, uPAR uses three copies of this domain type-although in a different arrangement-to form a C-clamp-like structure for enveloping an EGF domain 9, 19 .
as described 5 . The EGF domain of Spitz (residues 48-99; Spitz EGF ) was generated by proteolytic cleavage of a modified form of secreted full-length Spitz produced in transfected Drosophila S2 cells. Crystals were grown using the hanging-drop method. Crystals grew from a 1:1 Argos 217 :Spitz EGF mixture (250 mM complex) at pH 7, using PEG20000 as the precipitant, or from a 250 mM solution of Argos 217 alone using PEG3350 as precipitant (at pH 4.5). Crystals of Spitz EGF alone (500 mM) grew in ammonium sulphate, pH 6.5. Structure determination. The Argos 217 -Spitz EGF complex structure was determined by MAD with the halide soak method 10 . Crystallographic data were collected at the Advanced Photon Source and the Advanced Light Source, as summarized in Supplementary Table 1 . Phasing from ten ordered bromide ions yielded a readily interpretable electron-density map allowing nearly the entire chain of each complex to be traced. Alternating cycles of model building with COOT 28 and refinement with REFMAC 29 led to a complete model of Argos 217 and Spitz EGF with R cryst and R free values of 0.20 and 0.24, respectively, to 1.6 Å resolution (Supplementary Table 1 ). The unliganded Argos 217 structure was solved by sequential molecular replacement using PHASER in the CCP4 suite of programs 29 , and the Spitz EGF structure was solved by molecular replacement using a loop-truncated version of the hEGF domain structure (1JL9) 30 .
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
